Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESPR Esperion Therapeutics

Trading 02-06 10:12:55 EST

3.34

+0.16

+4.87%

High3.34	Low3.22	Vol553.62K
Open3.25	D1 Closing3.18	Amplitude3.77%
Mkt Cap797.28M	Tradable Cap790.40M	Total Shares239.06M
T/O1.81M	T/O Rate0.23%	Tradable Shares237.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics","latestPrice":3.335,"timestamp":1770390759158,"preClose":3.18,"halted":0,"volume":553624,"delay":0,"changeRate":0.04874213836477981,"floatShares":237000000,"shares":239063437,"eps":-0.535792,"marketStatus":"Trading","change":0.155,"latestTime":"02-06 10:12:55 EST","open":3.25,"high":3.34,"low":3.22,"amount":1814625.7859776,"amplitude":0.037736,"askPrice":3.34,"askSize":2510,"bidPrice":3.33,"bidSize":1743,"shortable":3,"etf":0,"ttmEps":-0.535792,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770411600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":3.18,"preHourTrading":{"tag":"盘前","latestPrice":3.25,"preClose":3.18,"latestTime":"09:10 EST","volume":1401,"amount":4471.430199,"timestamp":1770387050876,"change":0.07,"changeRate":0.022013,"amplitude":0.022013},"postHourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.18,"latestTime":"19:59 EST","volume":404052,"amount":1284765.1107,"timestamp":1770339546464,"change":-0.01,"changeRate":-0.003145,"amplitude":0.037956},"volumeRatio":1.292071,"impliedVol":0.7671,"impliedVolPercentile":0.494},"requestUrl":"/m/hq/s/ESPR","defaultTab":"news","newsList":[{"id":"2606219734","title":"Esperion (ESPR) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2606219734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606219734?lang=en_us&edition=fundamental","pubTime":"2026-01-28 02:06","pubTimestamp":1769537170,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Esperion today and set a price target of $16.00. According to TipRanks, Pantgin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/esperion-espr-gets-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/esperion-espr-gets-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2603913199","title":"Piper Sandler Sticks to Their Buy Rating for Esperion (ESPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603913199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603913199?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:53","pubTimestamp":1768571590,"startTime":"0","endTime":"0","summary":"In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Esperion, with a price target of $9.00. According to TipRa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-esperion-espr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-esperion-espr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR"],"gpt_icon":0},{"id":"2602566173","title":"Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602566173","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602566173?lang=en_us&edition=fundamental","pubTime":"2026-01-12 08:25","pubTimestamp":1768177516,"startTime":"0","endTime":"0","summary":"“2025 marked the most successful year in Esperion’s (ESPR) history, driven by exceptional execution across our U.S. commercial strategy, expanded g...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-reports-preliminary-fy25-revenue-400m-408m-consensus-393-11m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-reports-preliminary-fy25-revenue-400m-408m-consensus-393-11m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2602563452","title":"BRIEF-Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563452","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563452?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:04","pubTimestamp":1768172662,"startTime":"0","endTime":"0","summary":"BRIEF-Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product SalesJan 11 (Reuters) - Esperion Therapeutics Inc ESPR.O:ESPERION PROVIDES BUSINESS UPDATE AT 44TH ANNUAL J.P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA7LMSHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2602174563","title":"Esperion Therapeutics Projects 2025 Revenue Up to $408 Million and Operating Expenses Up to $245 Million for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602174563","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602174563?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172415,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. released its preliminary financial outlook for full-year 2025, projecting U.S. net product sales between $156 million and $160 million, representing a 35% to 38% increase compared to 2024. Total preliminary revenue is expected to reach $400 million to $408 million, up 20% to 23% year-over-year, and reflecting approximately 55% to 59% growth when excluding one-time milestone payments. The company reported cash and cash equivalents of approximately $168 million at year-end 2025. Operating expenses for full-year 2026 are anticipated to be between $210 million and $245 million. Esperion highlighted significant growth in its cardiovascular franchise and retail prescription equivalents, which increased 34% year-over-year and 11.3% quarter-over-quarter in Q4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL3yCSNy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","ESPR","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014039.USD","LU0314104364.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2602451563","title":"Esperion Therapeutics Inc - Reports $156 to $160 Mln in Preliminary* Full-Year 2025 U.S. Net Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2602451563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602451563?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA7LMSHG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2602178563","title":"Esperion Provides Business Update at 44TH Annual J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602178563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602178563?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA7LMSHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2602563457","title":"Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563457","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563457?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172400,"startTime":"0","endTime":"0","summary":"– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216503/0/en/Esperion-Provides-Business-Update-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0267386448.USD","LU2023251221.USD","LU1732799900.SGD","LU1989772923.USD","LU2271345857.HKD","ESPR","HCSG","LU0098860793.USD","LU0971096721.USD","LU1732800096.USD","LU1791710400.SGD","BK4516","IE00BZ1G4Q59.USD","LU1989772840.SGD","LU1074936037.SGD","LU1668664300.SGD","LU1791710582.SGD","BK4137","LU1720051017.SGD","LU2133065610.SGD","BK4534","LU0528227936.USD","LU0106831901.USD","LU2089284900.SGD","LU0912757837.SGD","LU0234570918.USD","LU2028103732.USD","BK4082","LU1244550577.SGD","IE00BKVL7J92.USD","PSC","LU0882574139.USD","LU0029874061.USD","BK4127","BK4588","LU0158827781.USD","XLV","LABU","LU2111349929.HKD","CV","LU0128526141.USD","LU0320765646.SGD","XBI","LU0225283273.USD","LU1162221912.USD","LU0106261372.USD","LU0006306889.USD","LU0795875086.SGD","LU2357305700.SGD"],"gpt_icon":0},{"id":"2590632216","title":"BRIEF-Esperion Announces Inducement Grants Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2590632216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590632216?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:13","pubTimestamp":1765318386,"startTime":"0","endTime":"0","summary":"BRIEF-Esperion Announces Inducement Grants Under Nasdaq Listing Rule Dec 9 (Reuters) - Esperion Therapeutics Inc ESPR.O:ESPERION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nGNXbsRbLzFurther company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA6S64WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2590647324","title":"Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590647324","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590647324?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:30","pubTimestamp":1765315801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA6S64WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2590132288","title":"Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590132288","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590132288?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:30","pubTimestamp":1765315800,"startTime":"0","endTime":"0","summary":"ANN ARBOR, Mich., Dec.  09, 2025  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purch","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202793/0/en/Esperion-Announces-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","QLD","SQQQ","ESPR","TQQQ","NQmain","NVIW.SI","TSYW.SI","PSQ","USJW.SI","QID","USAW.SI",".IXIC","BK4007"],"gpt_icon":1},{"id":"2586036204","title":"Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2586036204","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586036204?lang=en_us&edition=fundamental","pubTime":"2025-11-26 02:41","pubTimestamp":1764096093,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics  shares were up over 15% in recent Tuesday trading after Piper Sandler began coverage of the healthcare company's stock with an overweight rating and a $9 price target.The company's trading volume for the day stood at about 13.8 million shares against a daily average of roughly 7 million.Price: 3.67, Change: +0.50, Percent Change: +15.62","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2586724874","title":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724874?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:45","pubTimestamp":1764085504,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KEYS","ANF","FLY","LU1066051498.USD","SCCO","ZETA","SG9999000418.SGD","IE00BN0W2T93.GBP","SPOT","ATAT","HL","KSS","ZM","ABCB","APD","DD","UPWK","PTCT","IRD","CDW","SRPT","FIBK","ALUR","LU0323591593.USD","BK4541","BK4548","CDE","AMAT","LU2290526834.HKD","SYM","FLNC","FCX","BBY","LU1815336760.USD","ESPR","LU1116320737.USD","LIXT","VST","TITN","LU0784383803.USD","ADI"],"gpt_icon":1},{"id":"2586026479","title":"Esperion Therapeutics Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2586026479","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586026479?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:29","pubTimestamp":1764080940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 09:29 ET (14:29 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR"],"gpt_icon":0},{"id":"2586442049","title":"Piper Sandler Initiates Coverage on Esperion Therapeutics With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586442049","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586442049?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:16","pubTimestamp":1764072993,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (ESPR) has an average rating of overweight and mean price target of $6.47, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ESPR"],"gpt_icon":0},{"id":"2586427196","title":"BUZZ-Esperion gains after Piper Sandler initiates with 'overweight' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586427196","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586427196?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:50","pubTimestamp":1764071412,"startTime":"0","endTime":"0","summary":"BUZZ-Esperion gains after Piper Sandler initiates with 'overweight' rating** Shares of drug developer Esperion Therapeutics ESPR.O gain 1.4% to $3.22 premarket** Piper Sandler initiates with \"overweig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4127","PIPR","BK4007"],"gpt_icon":0},{"id":"2586429701","title":"Esperion initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2586429701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586429701?lang=en_us&edition=fundamental","pubTime":"2025-11-25 18:10","pubTimestamp":1764065428,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem last night initiated coverage of Esperion (ESPR) with an Overweight rating and $9 price target The company’s b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-initiated-with-an-overweight-at-piper-sandler-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-initiated-with-an-overweight-at-piper-sandler-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2586086442","title":"U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2586086442","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586086442?lang=en_us&edition=fundamental","pubTime":"2025-11-25 15:29","pubTimestamp":1764055799,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale CapitalNov 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, inclu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10CW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRT","LU0238689110.USD","BK4549","ZM","LU1543694498.USD","COCO","BK4588","LUMN","EXAS","BK4223","HL","NWSA","LMND","TWFG","LU2322448791.USD","LU1169589451.USD","OKTA","BK4560","AXGN","EHTH","ESPR","LU2041044095.USD","LU2272731782.SGD","LU2272731865.HKD","LU0106261612.USD","BOW","CUZ","MMC","A","LU2413666699.HKD","INSP","APD","IE00BMPRXR70.SGD","KNSL","BJ","SNEX","KEYS","CENT","SIGI","BK4007","BK4173","SMTC","THG","LU2092937221.SGD","BK4082","HIG","EPRT","BK4548","DEI","BK4179"],"gpt_icon":0},{"id":"2586445056","title":"Esperion Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2586445056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586445056?lang=en_us&edition=fundamental","pubTime":"2025-11-25 12:43","pubTimestamp":1764045802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X00NU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2585128696","title":"BUZZ-U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet","url":"https://stock-news.laohu8.com/highlight/detail?id=2585128696","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585128696?lang=en_us&edition=fundamental","pubTime":"2025-11-22 02:44","pubTimestamp":1763750694,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, AlphabetEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nL6N3WX0O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NFE","BBWI","BJ","NVDD","LOW","OGE","GOOGL","NVD2.UK","RIOT","DOCS","ANAB","NVD3.UK","IESC","WDAY","PHM","CPRT","NVDY","NVD","LU0868494708.USD","LU1880398471.USD","VFS","INTU","ESPR","NVDS","AHR","NVRI","SNVD.UK","AZTA","GAP","NVIW.SI","DHI","3NVD.UK","NVDS.UK","NVDU","TMUS","2NVD.UK","LU0957808578.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":-0.1042},{"period":"1month","weight":-0.1452},{"period":"3month","weight":0.1955},{"period":"6month","weight":0.7005},{"period":"1year","weight":0.6825},{"period":"ytd","weight":-0.1405}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.043403},{"month":2,"riseRate":0.461538,"avgChangeRate":0.110005},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027865},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.028114},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.032489},{"month":6,"riseRate":0.75,"avgChangeRate":0.035061},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Esperion Therapeutics,ESPR,Esperion Therapeutics股票,Esperion Therapeutics股票老虎,Esperion Therapeutics股票老虎国际,Esperion Therapeutics行情,Esperion Therapeutics股票行情,Esperion Therapeutics股价,Esperion Therapeutics股市,Esperion Therapeutics股票价格,Esperion Therapeutics股票交易,Esperion Therapeutics股票购买,Esperion Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}